Significantly, we revealed that the survival of EPHA5-mutant (Mut) LUAD patients was more favorable than that of EPHA5-WT patients in an immunotherapy setting, providing new insight into the search for predictive biomarkers for the immunotherapy response in lung cancer. This evidence concerns the gene EPHA5 and lung carcinoma.